In recent clinical studies, high PD-L1 expression on tumour-infiltrating immune cells also correlates to higher survival rates to both anti-PD-L1 monotherapy and combination therapy with nanoparticle albumin-bound (nab)-paclitaxel in metastatic TNBC [11,12]. The gene discussed is CD274; the disease is neoplasm.